Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
This article was originally published in The Tan Sheet
Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants
You may also be interested in...
An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.
FDA's dietary supplement good manufacturing practices, while imposed to help assure safe nutritionals reach the market, are creating costs that could drive more firms to file new drug applications for natural products, according to a pair of regulatory experts
The Global Organization for EPA and DHA Omega-3s expands its board of directors as the increasing use of fish oil across the food and drug industries spurs membership growth